Longeveron LGVN 深 沪
已收盘 09-04 16:00:00 美东时间
6.81
+0.230
+3.50%
华盛通- 最 高6.88
- 今 开6.54
- 成交量 4.12万股
- 最 低 6.53
- 昨 收 6.58
- 总市值 2171.16万
- 52周最高 12.30
- 市盈率 静 --
- 换手率 1.29%
- 52周最低 4.75
- 委 比 -81.57%
- 总股本 318.82万
- 历史最高 4500.00
- 量 比 0.69
- 振 幅 5.32%
- 历史最低 4.75
- 每 手 1
- 风险率 1.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Dick’s Sporting Goods Inc. (NYSE:DKS) to post quarterly earnings of $3.77 per share on revenue of $5.65 billion before the opening bell, according ...
08-25 16:02
Longeveron Announces 1-for-10 Reverse Stock Split, Expected To Become Effective August 26
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.00...
08-25 04:07
Longeveron Announces 1-for-10 Reverse Stock Split
Longeveron Inc. (NASDAQ: LGVN) announced a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq’s $1.00 minimum bid requirement. Effective August 26, 2026, the split aims to align the company’s share structure with future opportunities and institutional investor preferences. CEO Stephen Willard emphasized that the reverse split is a structural adjustment without altering the company’s strategy or operations. ...
08-24 20:05
Longeveron Inc. Earnings Call: Trials, Cash and Risk
Longeveron Inc. (($LGVN)) has held its Q2 earnings call. Read on for the main h...
08-23 08:25
Longeveron Appoints Nirav Jhaveri CFO, Succeeding Marie Washburn
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Ch...
08-20 04:07
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...
08-19 20:05
朗吉维龙 (LGVN) 2026年第二季度业绩电话会：ELPIS II数据将于9月公布
Longeveron 2026年第二季度业绩电话会议：ELPIS II HLHS数据将于9月公布，净亏损扩大至610万美元，现金总额为1010万美元。
08-14 08:27
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Longeveron Inc. has been selected as a Milestone 2 Awardee in the XPRIZE Healthspan competition, receiving $1 million to advance its stem cell therapy, laromestrocel, which has shown promise in clinical trials for conditions like aging-related frailty, Alzheimer’s disease, and HLHS. The competition aims to develop therapies that restore muscle, cognition, and immune function in adults aged 50-90 by at least 10 years within one year of treatment.
08-11 13:05
Longeveron Restores Nasdaq Compliance with New Audit Committee
Longeveron ( ($LGVN) ) just unveiled an announcement. In March 2026, Longeveron...
07-30 04:42
